Merck to develop USD 1.3 billion research center in London by 2025

By Nikita Chaurasia  Date: 2020-08-19

Merck to develop USD 1.3 billion research center in London by 2025

America-based leading pharmaceutical company Merck & Co. Inc. (MSD) is reportedly moving ahead with its plans of building a research center in London. Sources close to the matter stated that the new facility, which will be known as London Discovery Research Centre, is valued at USD 1.3 billion and is estimated to be operational by the year 2025.

The project was initially announced in 2017 as a part of Merck’s initiative to support Britain post-Brexit, although it was delayed owing to the limitations in finding adequate space in the city, sources claimed. In addition to this, Merck intends to build its life sciences center near the Francis Crick Institute in the northern part of London.

However, the deal is yet to be finalized since it apparently requires the approval of London Borough of Camden. If sources are to be believed, work on the research center is anticipated to start late in 2021, with the facility providing over 120 jobs for technicians as well as researchers.

It appears that the site will be around 25,000 square meters and Merck intends to hire around 800 staff. Sources further stated that the research teams at the site will conduct early-stage diagnostics and majorly focus on age-related disorders.

MSD Managing Director for Ireland and UK, David Peacock, was reported saying that the company views the United Kingdom as a leader in developing science, which is primarily driven by the country’s long-term focus on developing a robust R&D infrastructure.

It is to be noted that Merck had entered a five-year joint venture agreement with Crick Institute to promote research & development in neuroscience. Although Merck’s research projects were conducted independently, the team was completely integrated into the scientific community of Crick Institute.

In fact, research teams from Merck and Crick collaborated in August 2019, in an effort to analyze the cause of Motore Neurone Disease, which was the first combined project since the initial five-year partnership.

Source Credits –

https://www.biospace.com/article/merck-to-build-1-31-billion-research-hub-in-london/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Netflix confirms producing fictionalized version of Spotify’s ascension

Netflix confirms producing fictionalized version of Spotify’s ascension

By Nikita Chaurasia

Over-the-top content streaming & production giant Netflix Inc. is reportedly working on an untitled series that tells the story of one of the most successful music streaming companies, Spotify Ltd. The six-part series, already listed on Netflix,...

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

By Nikita Chaurasia

Byju’s, the largest education technology company, has emerged as India’s highest-valued startup after a USD 340 million funding round involving investors such as UBS Group, Blackstone, and Zoom founder Eric Yuan among others. Recently, B...

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

By Nikita Chaurasia

Hesai Photonics Technology Co. Ltd., a leading Shanghai-based LiDAR company, has reportedly secured USD 300 million in a Series D funding round which was led by GL Ventures LLC, Xiaomi Corporation, Hillhouse Capital Group, Meituan, and CPE. The roun...

Tesla terminates production of its Model S Plaid + variant indefinitely

Tesla terminates production of its Model S Plaid + variant indefinitely

By Nikita Chaurasia

CEO Elon Musk justified Model S Plaid as good enough against its successor. The Model S Plaid + was touted to be Tesla’s flagship vehicle, with a range of around 519 miles. After unveiling for the first time last year, American EV maker T...

ByHeart concludes largest U.S. clinical trial for infant food product

ByHeart concludes largest U.S. clinical trial for infant food product

By Nikita Chaurasia

ByHeart Inc., a New-York based infant, and baby nutrition company, has recently announced the completion of the largest clinical trial for new infant formula in the past 25 years. With this move, the company is earmarked to be the 4th FDA registered,...